These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33299166)

  • 1. CRISPR gene therapy shows promise against blood diseases.
    Ledford H
    Nature; 2020 Dec; 588(7838):383. PubMed ID: 33299166
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment by CRISPR-Cas9 Gene Editing - A Proof of Principle.
    Malech HL
    N Engl J Med; 2021 Jan; 384(3):286-287. PubMed ID: 33471982
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Meisel R
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107195
    [No Abstract]   [Full Text] [Related]  

  • 5. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Mehta J
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
    [No Abstract]   [Full Text] [Related]  

  • 6. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
    Duroux-Richard I; Giovannangeli C; Apparailly F
    Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
    [No Abstract]   [Full Text] [Related]  

  • 8. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.
    Frangoul H; Ho TW; Corbacioglu S
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107197
    [No Abstract]   [Full Text] [Related]  

  • 9. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
    Liu W; Yang C; Liu Y; Jiang G
    Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology].
    Bao LW; Zhou YY; Zeng FY
    Yi Chuan; 2020 Oct; 42(10):949-964. PubMed ID: 33229321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cas9 immunity creates challenges for CRISPR gene editing therapies.
    Crudele JM; Chamberlain JS
    Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes.
    Soyars CL; Peterson BA; Burr CA; Nimchuk ZL
    Plant Cell Physiol; 2018 Aug; 59(8):1608-1620. PubMed ID: 29912402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meeting Report: German Genetics Society-Genome Editing with CRISPR.
    Maier LK; Marchfelder A; Randau L
    Bioessays; 2020 Feb; 42(2):e1900223. PubMed ID: 31853989
    [No Abstract]   [Full Text] [Related]  

  • 17. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
    Cheng X; Fan S; Wen C; Du X
    Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
    Parums DV
    Med Sci Monit; 2024 Mar; 30():e944204. PubMed ID: 38425279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinued CRISPR gene therapy for sickle-cell disease improves symptoms.
    Carvalho T
    Nat Med; 2023 Nov; 29(11):2669-2670. PubMed ID: 37783810
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.